Study on Rilvegostomig or Durvalumab with Chemotherapy for First-Time Treatment of Biliary Tract Cancer

Inclusion Criteria

• Diagnosed with adenocarcinoma of the biliary tract, including types like intra-hepatic or extra-hepatic cholangiocarcinoma and gallbladder carcinoma.
• Cancer that cannot be surgically removed or has spread, and has not been treated before in its advanced stage.
• Known PD-L1 status, determined by a central lab using a suitable tumor sample.
• Cancer that can be measured accurately using CT or MRI scans.
• In good general health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate bone marrow and organ function as determined by specific medical tests.

Exclusion Criteria

• Have ampullary carcinoma.
• Have received any previous systemic therapy for advanced biliary tract cancer.
• Have been treated with any other therapies targeting immune system receptors or mechanisms.
• Are currently receiving any other cancer treatments, such as chemotherapy, radiotherapy, or immunotherapy, not included in this study.
• Have active or previously documented autoimmune or inflammatory disorders that require ongoing treatment with steroids or other immunosuppressive medications.
• Have active lung disease or inflammation, serious chronic digestive conditions causing diarrhea, or active skin diseases requiring systemic treatment.